Chemomab Therapeutics Ltd Stock Price, News & Analysis

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a biotechnology firm specializing in innovative therapeutics for fibro-inflammatory diseases, announced its participation in the Aegis 2023 Virtual Investor Conference from May 2 to May 4, 2023. Chemomab's management will present a corporate overview on May 3, 2023, at 9:00 AM EDT. The event will be held virtually, and investors can access the webcast through a provided link.

Additionally, Chemomab's corporate development team will attend the BIO International Convention's One-on-One Partnering™ event in Boston from June 5 to June 8, 2023. They encourage registered attendees to schedule meetings via an online portal.

The company focuses on creating therapies like CM-101, a monoclonal antibody aimed at treating severe fibro-inflammatory diseases, backed by ongoing Phase 2 trials.

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) announced its participation in several scientific conferences during April and May 2023. Key events include the British Society for Rheumatology Annual Conference from April 24-26, where Chemomab will present an oral presentation on CCL24 serum concentration and its relevance in systemic sclerosis. The second event is the EASL Monothematic Conference on Biliary Fibrosis from May 12-13, highlighting a poster presentation on the role of CCL24 in cholestatic disease. Additionally, Chemomab's corporate development team will attend the BIO International Convention in Boston from June 5-8, focusing on partnership opportunities. Chemomab aims to advance innovative therapeutics for fibro-inflammatory diseases, particularly through its monoclonal antibody CM-101, which targets CCL24.

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotechnology company, will hold a webcast and conference call on May 11, 2023, at 8:00 am ET to discuss its first quarter 2023 financial results and provide a corporate update. This event replaces a previous update originally set for April 17, 2023. During the call, the management team will review the company's performance, recent developments, and host a Q&A session. A replay will be available on their website for 90 days. Chemomab focuses on developing therapeutics for fibro-inflammatory diseases and has seen promising results from its lead product, CM-101, in various ongoing studies.

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) will hold a Corporate Update on April 17, 2023, at 8:00 am Eastern Time. This replaces a previously scheduled webcast on March 31, 2023. The management team will review recent developments and answer questions from investors. Chemomab focuses on innovative therapies for fibro-inflammatory diseases, with CM-101 showing promise in trials for liver fibrosis and severe lung injury in COVID-19 patients. A Phase 2 trial for primary sclerosing cholangitis is ongoing, and a similar trial for systemic sclerosis is expected to open mid-2023.

Chemomab Therapeutics (Nasdaq: CMMB) will present its Q4 and full-year 2022 financial results on March 31, 2023, at 8:00 am Eastern Time. The management team will review the company’s performance and discuss future developments during the call, which includes a live question-and-answer session. Notably, the company focuses on developing therapeutics to address fibro-inflammatory diseases. Their key product, CM-101, aims to treat severe diseases related to fibrosis and inflammation, with recent positive results from clinical studies. A replay of the event will be available for 90 days on their website.

Chemomab Therapeutics, a clinical-stage biotech company focused on fibro-inflammatory diseases, will present a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023. The conference will be held virtually, with the presentation scheduled for 9:20 am ET. Investors can also request 1-on-1 meetings with management through Oppenheimer representatives. Chemomab is advancing its lead product, CM-101, targeting fibrosis and inflammation. Recent developments include completing a Phase 2 liver fibrosis biomarker study and preparing for a Phase 2 trial in systemic sclerosis in the first half of 2023. More details are available at investors.chemomab.com/events.

Chemomab Therapeutics (CMMB) received FDA clearance for the Phase 2 ABATE trial to evaluate CM-101 in patients with systemic sclerosis (SSc). The trial aims to assess safety and establish proof-of-concept for CM-101, a monoclonal antibody targeting fibrosis in SSc. CM-101 has shown promise in preclinical studies, reducing fibrotic injury in affected organ systems. The ABATE trial targets 45 patients and emphasizes safety as its primary endpoint, with results anticipated in the second half of 2024. CM-101 is positioned to potentially become the first disease-modifying treatment for SSc, a condition affecting approximately 100,000 patients in the U.S.

Chemomab Therapeutics (CMMB) announced positive results from its Phase 2a trial of CM-101 in NASH patients. The trial met its primary endpoint of safety and tolerability, with most adverse events being mild. CM-101 demonstrated significant reductions in liver fibrosis biomarkers, with nearly 60% of treated patients improving in three or more biomarkers. The trial included 23 patients receiving either CM-101 or placebo over 16 weeks. These findings reinforce Chemomab's ongoing optimism for CM-101's potential in treating fibrotic diseases.

Chemomab Therapeutics (Nasdaq: CMMB) announced a positive safety review from an independent Data Monitoring Committee for its ongoing Phase 2 trial of CM-101 in patients with primary sclerosing cholangitis (PSC). The DMC found no safety concerns in advancing to a higher dose cohort of 20 mg/kg, alongside the current 10 mg/kg dosing. CM-101, a monoclonal antibody targeting CCL24, aims to treat fibrotic and inflammatory diseases. Top-line results from this PSC trial are expected in H2 2024, with additional insights from a separate liver fibrosis biomarker trial anticipated soon.